-
1 Comment
Ergomed plc is currently in a long term uptrend where the price is trading 14.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Finally, its free cash flow grew by 14.6% to $5M since the same quarter in the previous year.
Based on the above factors, Ergomed plc gets an overall score of 3/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | GB00BN7ZCY67 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 789M |
---|---|
PE Ratio | 44.48 |
Target Price | None |
Dividend Yield | 0.0% |
Beta | 0.79 |
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2EM.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025